Actualités Eyetech Pharmaceuticals (MM) - EYET | Actions NASDAQ

Schaeffer's Midday Options Update Features General Motors, Citigroup, Northrop Grumman, Intel, and Eyetech Pharmaceuticals

Today's Schaeffer's Midday Options Update features General Motors (NYSE:GM), Citigroup (NYSE:C), Northrop Grumman (NYSE:NOC), Intel (Nasdaq:INTC...

Eyetech Announces Appointment of Henry Simon as Chairman of the Board and Resignation of John McLaughlin

Eyetech Announces Appointment of Henry Simon as Chairman of the Board and Resignation of John McLaughlin NEW YORK, June 10...

Eyetech Adopts Stockholder Rights Agreement

Eyetech Adopts Stockholder Rights Agreement NEW YORK, June 9 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET), a...

Eyetech Announces Conference Call to Reiterate Confidence in Macugen(R) (Pegaptanib Sodium Injection)

Eyetech Announces Conference Call to Reiterate Confidence in Macugen(R) (Pegaptanib Sodium Injection) NEW YORK, May 24 /PRNewswire-FirstCall/...

Eyetech Announces Approval of Macugen(R) in Brazil for the Treatment of Neovascular (Wet) Age-Related Macular Degeneration

Eyetech Announces Approval of Macugen(R) in Brazil for the Treatment of Neovascular (Wet) Age-Related Macular Degeneration -- First treatment that...

Eyetech to Present at the 2005 UBS Global Pharmaceuticals Conference

Eyetech to Present at the 2005 UBS Global Pharmaceuticals Conference NEW YORK, May 10 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals...

Eyetech Announces Approval of Macugen(R) in Canada for The Treatment of Neovascular (Wet) Age Related Macular Degeneration

Eyetech Announces Approval of Macugen(R) in Canada for The Treatment of Neovascular (Wet) Age Related Macular Degeneration -- First treatment that...

Macugen(R) (pegaptanib sodium injection) Studied in Treatment of Diabetic Macular Edema (DME) and Other Diabetic Retinopathy Les

Macugen(R) (pegaptanib sodium injection) Studied in Treatment of Diabetic Macular Edema (DME) and Other Diabetic Retinopathy Lesions Improvement...

Safety Profile of Macugen(R) (pegaptanib sodium injection) in the Treatment of Neovascular Age-Related Macular Degeneration (AMD

Safety Profile of Macugen(R) (pegaptanib sodium injection) in the Treatment of Neovascular Age-Related Macular Degeneration (AMD) Maintained...

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Eyetech Pharmaceuticals (MM) (EYET)

Outils de qualité professionnelle, pour des investisseurs individuels.

EYET Actualités

Schaeffer's Midday Options Update Features General Motors, Citigroup, Northrop Grumman, Intel, and Eyetech Pharmaceuticals

Eyetech Announces Appointment of Henry Simon as Chairman of the Board and Resignation of John McLaughlin

Eyetech Adopts Stockholder Rights Agreement

Eyetech Announces Conference Call to Reiterate Confidence in Macugen(R) (Pegaptanib Sodium Injection)

Eyetech Announces Approval of Macugen(R) in Brazil for the Treatment of Neovascular (Wet) Age-Related Macular Degeneration

Eyetech to Present at the 2005 UBS Global Pharmaceuticals Conference

Eyetech Announces Approval of Macugen(R) in Canada for The Treatment of Neovascular (Wet) Age Related Macular Degeneration

Macugen(R) (pegaptanib sodium injection) Studied in Treatment of Diabetic Macular Edema (DME) and Other Diabetic Retinopathy Les

Safety Profile of Macugen(R) (pegaptanib sodium injection) in the Treatment of Neovascular Age-Related Macular Degeneration (AMD

Eyetech to Present at Morgan Stanley's Third Annual Global Healthcare Unplugged Conference

Eyetech Reports First Quarter 2005 Financial Results

Eyetech to Announce First Quarter 2005 Financial Results on April 20, 2005

Eyetech to Present at the Smith Barney Citigroup 2005 Healthcare Conference

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Eyetech Pharmaceuticals (MM) (EYET) Actualités

Eyetech Pharmaceuticals (MM) (EYET)

Outils de qualité professionnelle, pour des investisseurs individuels.

EYET Actualités

Schaeffer's Midday Options Update Features General Motors, Citigroup, Northrop Grumman, Intel, and Eyetech Pharmaceuticals

Eyetech Announces Appointment of Henry Simon as Chairman of the Board and Resignation of John McLaughlin

Eyetech Adopts Stockholder Rights Agreement

Eyetech Announces Conference Call to Reiterate Confidence in Macugen(R) (Pegaptanib Sodium Injection)

Eyetech Announces Approval of Macugen(R) in Brazil for the Treatment of Neovascular (Wet) Age-Related Macular Degeneration

Eyetech to Present at the 2005 UBS Global Pharmaceuticals Conference

Eyetech Announces Approval of Macugen(R) in Canada for The Treatment of Neovascular (Wet) Age Related Macular Degeneration

Macugen(R) (pegaptanib sodium injection) Studied in Treatment of Diabetic Macular Edema (DME) and Other Diabetic Retinopathy Les

Safety Profile of Macugen(R) (pegaptanib sodium injection) in the Treatment of Neovascular Age-Related Macular Degeneration (AMD

Eyetech to Present at Morgan Stanley's Third Annual Global Healthcare Unplugged Conference

Eyetech Reports First Quarter 2005 Financial Results

Eyetech to Announce First Quarter 2005 Financial Results on April 20, 2005

Eyetech to Present at the Smith Barney Citigroup 2005 Healthcare Conference

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres